Clinical features, ASCT-relevant variables, and post-ASCT events according to JAK2V617F mutational state
| Variable/category . | JAK2-wt . | JAK2V617F . | P . |
|---|---|---|---|
| No. (%) of patients | 44 (32) | 95 (68) | |
| Median age, y (range) (n = 139)* | 59 (36-73) | 56 (32-72) | .2 |
| Males, no. (%) (n = 139)* | 22 (50) | 60 (63) | .2 |
| Diagnosis (n = 132) | < .001 | ||
| PMF | 29 (69) | 53 (59) | |
| Post-PV MF | 0 (0) | 24 (27) | |
| Post-ET MF | 13 (31) | 13 (14) | |
| Median time, mo (range), from diagnosis to SCT (n = 130)* | 47 (3-360) | 61 (3-272) | .1 |
| Cytogenetics, no. (%) (n = 82)* | .4 | ||
| Favorable | 2 (40) | 3 (60) | |
| Normal | 13 (29) | 32 (71) | |
| Others | 3 (15) | 17 (85) | |
| Unfavorable | 5 (42) | 7 (58) | |
| Lille score, no. (%) (n = 135)* | .4 | ||
| Low | 7 (16) | 24 (26) | |
| Intermediate | 27 (61) | 48 (53) | |
| High | 10 (23) | 19 (21) | |
| Transfusion dependency, no. (%) (n = 131)* | .1 | ||
| No transfusions | 13 (33) | 44 (48) | |
| Transfusion-dependent | 27 (68) | 47 (52) | |
| IPSS, no. (%) (n = 131)* | .1 | ||
| Low | 1 (2) | 2 (2) | |
| Intermediate-1 | 8 (20) | 14 (16) | |
| Intermediate-2 | 9 (22) | 38 (42) | |
| High | 23 (56) | 36 (40) | |
| CMV status (n = 134)* | |||
| CMV+ recipients, no. (%) | 19 (46) | 55 (59) | |
| Donors, no. (%) (n = 139)* | .7 | ||
| MRD | 12 (27) | 28 (30) | |
| MUD | 21 (48) | 49 (51) | |
| MMUD | 11 (25) | 18 (19) | |
| Conditioning, no. (%) (n = 139)* | .5 | ||
| Busulfan/fludarabine-based | 41 (93) | 88 (93) | |
| Treosulfan/fludarabine | 1 (2) | 5 (5) | |
| Others | 2 (5) | 2 (2) | |
| Median no. (range) of infused CD34+ infused stem cells/kg BW (n = 132)* | 6.4 (0.6-13.9) | 7.9 (1-21.6) | .4 |
| Median time, d (range), to engraftment (n = 128)* | 15 (10-59) | 16 (9-47) | .2 |
| Acute GVHD (n = 99)* | .5 | ||
| Grade II-IV acute GVHD, no. (%) | 6 (22) | 22 (31) | |
| Chronic GVHD (n = 97)* | .6 | ||
| Extensive chronic GVHD, no. (%) | 8 (30) | 17 (24) | |
| Primary graft failure, no. (%) | |||
| Secondary graft dysfunction, no. (%) | 9 (21) | 4 (4) | .004 |
| Deaths, no. (%) | 22 (50) | 24 (25) | .006 |
| Cause of death, no. (%) | .4 | ||
| Relapse | 7 (32) | 4(17) | |
| Toxicity | 2 (9) | 2 (8) | |
| GVHD | 3 (14) | 8 (33) | |
| Sepsis | 8 (36) | 5 (21) | |
| Bleeding | 0 (0) | 1 (4) | |
| Unclear | 2 (9) | 4 (17) |
| Variable/category . | JAK2-wt . | JAK2V617F . | P . |
|---|---|---|---|
| No. (%) of patients | 44 (32) | 95 (68) | |
| Median age, y (range) (n = 139)* | 59 (36-73) | 56 (32-72) | .2 |
| Males, no. (%) (n = 139)* | 22 (50) | 60 (63) | .2 |
| Diagnosis (n = 132) | < .001 | ||
| PMF | 29 (69) | 53 (59) | |
| Post-PV MF | 0 (0) | 24 (27) | |
| Post-ET MF | 13 (31) | 13 (14) | |
| Median time, mo (range), from diagnosis to SCT (n = 130)* | 47 (3-360) | 61 (3-272) | .1 |
| Cytogenetics, no. (%) (n = 82)* | .4 | ||
| Favorable | 2 (40) | 3 (60) | |
| Normal | 13 (29) | 32 (71) | |
| Others | 3 (15) | 17 (85) | |
| Unfavorable | 5 (42) | 7 (58) | |
| Lille score, no. (%) (n = 135)* | .4 | ||
| Low | 7 (16) | 24 (26) | |
| Intermediate | 27 (61) | 48 (53) | |
| High | 10 (23) | 19 (21) | |
| Transfusion dependency, no. (%) (n = 131)* | .1 | ||
| No transfusions | 13 (33) | 44 (48) | |
| Transfusion-dependent | 27 (68) | 47 (52) | |
| IPSS, no. (%) (n = 131)* | .1 | ||
| Low | 1 (2) | 2 (2) | |
| Intermediate-1 | 8 (20) | 14 (16) | |
| Intermediate-2 | 9 (22) | 38 (42) | |
| High | 23 (56) | 36 (40) | |
| CMV status (n = 134)* | |||
| CMV+ recipients, no. (%) | 19 (46) | 55 (59) | |
| Donors, no. (%) (n = 139)* | .7 | ||
| MRD | 12 (27) | 28 (30) | |
| MUD | 21 (48) | 49 (51) | |
| MMUD | 11 (25) | 18 (19) | |
| Conditioning, no. (%) (n = 139)* | .5 | ||
| Busulfan/fludarabine-based | 41 (93) | 88 (93) | |
| Treosulfan/fludarabine | 1 (2) | 5 (5) | |
| Others | 2 (5) | 2 (2) | |
| Median no. (range) of infused CD34+ infused stem cells/kg BW (n = 132)* | 6.4 (0.6-13.9) | 7.9 (1-21.6) | .4 |
| Median time, d (range), to engraftment (n = 128)* | 15 (10-59) | 16 (9-47) | .2 |
| Acute GVHD (n = 99)* | .5 | ||
| Grade II-IV acute GVHD, no. (%) | 6 (22) | 22 (31) | |
| Chronic GVHD (n = 97)* | .6 | ||
| Extensive chronic GVHD, no. (%) | 8 (30) | 17 (24) | |
| Primary graft failure, no. (%) | |||
| Secondary graft dysfunction, no. (%) | 9 (21) | 4 (4) | .004 |
| Deaths, no. (%) | 22 (50) | 24 (25) | .006 |
| Cause of death, no. (%) | .4 | ||
| Relapse | 7 (32) | 4(17) | |
| Toxicity | 2 (9) | 2 (8) | |
| GVHD | 3 (14) | 8 (33) | |
| Sepsis | 8 (36) | 5 (21) | |
| Bleeding | 0 (0) | 1 (4) | |
| Unclear | 2 (9) | 4 (17) |
CMV indicates cytomegalovirus; MRD, matched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; BW, body weight; and GVHD, graft-versus-host disease.
Available cases for evaluation in every category.